Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) RegionDecember 23, 2019

Emmaus Life Sciences, Inc., today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral powder) in certain countries in the Middle East and North Africa (MENA) region.

Emmaus Life Sciences Reports 2019 Third Quarter Financial ResultsNovember 12, 2019

Net Revenues Increased 25% Year-Over-Year, Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities

Emmaus Life Sciences Announces Equity Investment from a Corporate InvestorOctober 29, 2019

Vivozon, Inc. executes a stock purchase agreement for a total of $2.4 million.

Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended September 30, 2019October 11, 2019

Company Reports Highest Gross Sales Month of 2019 and Total Gross Sales of $7.0 Achieved in the Third Quarter.

Emmaus Life Sciences Granted Patent in India for use of Pharmaceutical-grade L-glutamine in Treating DiverticulosisOctober 09, 2019

Issuance by the Indian Patent Office Further Bolsters Emmaus’ International Intellectual Property Portfolio